ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,424.20
0.05%
Dow Jones
39,825.25
-0.45%
Gold vs US Dollar
2,434.915
0.63%
Brent Oil
83.555
-0.05%
Bitcoin
68,786.85
3.97%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) News

Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARQT
DateTimeSourceHeadlineSymbolCompany
17/05/202420:58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
14/05/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARQTArcutis Biotherapeutics Inc
14/05/202421:00GlobeNewswire Inc.Arcutis Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARQTArcutis Biotherapeutics Inc
14/05/202412:18IH Market NewsUS Futures Remain Steady Amid Wall Street Caution Ahead of April PPI ReportNASDAQ:ARQTArcutis Biotherapeutics Inc
13/05/202413:00GlobeNewswire Inc.Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic DermatologyNASDAQ:ARQTArcutis Biotherapeutics Inc
03/05/202421:00GlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
29/04/202421:00GlobeNewswire Inc.Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024NASDAQ:ARQTArcutis Biotherapeutics Inc
10/04/202413:00GlobeNewswire Inc.Arcutis Appoints David Topper as Chief Financial OfficerNASDAQ:ARQTArcutis Biotherapeutics Inc
05/04/202421:00GlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
01/04/202412:00GlobeNewswire Inc.Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamNASDAQ:ARQTArcutis Biotherapeutics Inc
28/03/202412:00GlobeNewswire Inc.Arcutis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
11/03/202412:00GlobeNewswire Inc.Arcutis Promotes Todd Tucker to Chief Human Resources OfficerNASDAQ:ARQTArcutis Biotherapeutics Inc
10/03/202420:00GlobeNewswire Inc.Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual MeetingNASDAQ:ARQTArcutis Biotherapeutics Inc
09/03/202421:00GlobeNewswire Inc.New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier DysfunctionNASDAQ:ARQTArcutis Biotherapeutics Inc
06/03/202422:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
06/03/202422:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
06/03/202422:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
05/03/202421:00GlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202422:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202422:42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202422:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202421:00GlobeNewswire Inc.Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202413:00GlobeNewswire Inc.Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual MeetingNASDAQ:ARQTArcutis Biotherapeutics Inc
01/03/202421:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
01/03/202421:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARQTArcutis Biotherapeutics Inc
29/02/202422:00GlobeNewswire Inc.Arcutis to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
29/02/202404:30GlobeNewswire Inc.Arcutis Announces Pricing of $150 Million Public OfferingNASDAQ:ARQTArcutis Biotherapeutics Inc
28/02/202421:54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
28/02/202421:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARQTArcutis Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ARQT

Your Recent History

LSE
CGO
Contango
NASDAQ
SNEN
LSE
HSUK
Hsbc Uk Sus Etf
LSE
ADV
Advance Energy
NASDAQ
SSP
EW Scripps
LSE
KIBO
Kibo Energy
LSE
ENET
Ethernity Networks
LSE
EVE
Esr 2022
BOV
CLXC34
Clorox
LSE
JOG
Jersey Oil And Gas
NYSE
TEF
Telefonica
NYSE
AWG
Alliance World
NASDAQ
APPN
Appian
NASDAQ
ECDA
ECD Automotive Design
NYSE
CAJ
Canon
LSE
REDX
Redx Pharma
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved